Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$264000.0.

  • Cyclerion Therapeutics' Cash from Operations rose 8461.54% to -$264000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 7794.35%. This contributed to the annual value of -$4.3 million for FY2024, which is 7960.46% up from last year.
  • According to the latest figures from Q3 2025, Cyclerion Therapeutics' Cash from Operations is -$264000.0, which was up 8461.54% from -$503000.0 recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Cash from Operations peaked at $360000.0 during Q4 2024, and registered a low of -$14.5 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$6.2 million (2023), whereas its average is -$5.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 9636.96% in 2022, then surged by 12336.15% in 2024.
  • Cyclerion Therapeutics' Cash from Operations (Quarter) stood at -$8.6 million in 2021, then increased by 18.39% to -$7.0 million in 2022, then surged by 78.12% to -$1.5 million in 2023, then surged by 123.36% to $360000.0 in 2024, then plummeted by 173.33% to -$264000.0 in 2025.
  • Its last three reported values are -$264000.0 in Q3 2025, -$503000.0 for Q2 2025, and -$968000.0 during Q1 2025.